Circulating tumor DNA as a liquid biopsy for cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Chemistry

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1373/clinchem.2014.222679PMID 25388429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of cell-free DNA as a biomarker for pancreatic malignancies

  2015cited by this paper
• Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification

  2014cited by this paper
• Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood.

  2014cited by this paper
• Direct Quantification of Cell-Free, Circulating DNA from Unpurified Plasma

  2014cited by this paper
• Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection

  2014cited by this paper
• Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

  2014cited by this paper
• Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing

  2014cited by this paper
• Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma

  2014cited by this paper
• Tumor Heterogeneity Confounds and Illuminates: Assessing the implications

  2014cited by this paper
• Changes in mutational status during third‐line treatment for metastatic colorectal cancer—Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma

  2014cited by this paper
• Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer.

  2014cited by this paper
• Abstract 5606: Detection of circulating tumor DNA in early and late stage human malignancies

  2014cited by this paper
• Implementing personalized cancer care

  2014cited by this paper
• Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis

  2014cited by this paper
• Cell‐free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer

  2014cited by this paper
• Multi‐marker analysis of circulating cell‐free DNA toward personalized medicine for colorectal cancer

  2014cited by this paper
• Computational optimisation of targeted DNA sequencing for cancer detection

  2013cited by this paper
• Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

  2013cited by this paper
• KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy

  2013cited by this paper
• An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

  2013cited by this paper
• Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing.

  2013cited by this paper
• Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.

  2013cited by this paper
• Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing

  2013cited by this paper
• Analysis of circulating tumor DNA to monitor metastatic breast cancer.

  2013cited by this paper
• Circulating tumor cells and DNA as liquid biopsies

  2013cited by this paper
• Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer

  2013cited by this paper
• Quantitation of cell-free DNA and RNA in plasma during tumor progression in rats

  2013cited by this paper
• High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing.

  2013cited by this paper
• Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer

  2013cited by this paper
• Early detection of nasopharyngeal carcinoma by plasma Epstein‐Barr virus DNA analysis in a surveillance program

  2013cited by this paper
• Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing

  2013cited by this paper
• Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

  2013cited by this paper
• Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer

  2013cited by this paper
• Overcoming implementation challenges of personalized cancer therapy

  2012cited by this paper
• Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

  2012cited by this paper
• Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing

  2012cited by this paper
• Genomic analysis of circulating cell-free DNA infers breast cancer dormancy.

  2012cited by this paper
• Loss of Heterozygosity at Tumor Suppressor Genes Detectable on Fractionated Circulating Cell-Free Tumor DNA as Indicator of Breast Cancer Progression

  2012cited by this paper
• Detection of ultra-rare mutations by next-generation sequencing

  2012cited by this paper
• The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

  2012cited by this paper
• Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan

  2012cited by this paper
• Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

  2012cited by this paper
• Tumour seeding following percutaneous needle biopsy: the real story!

  2011cited by this paper
• High Fragmentation Characterizes Tumour-Derived Circulating DNA

  2011cited by this paper
• Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

  2011cited by this paper
• Detection and quantification of rare mutations with massively parallel sequencing

  2011cited by this paper
• Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus

  2010cited by this paper
• Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts

  2010cited by this paper
• Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors

  2010cited by this paper
• Cell-Free Nucleic Acids Circulating in the Plasma of Colorectal Cancer Patients Induce the Oncogenic Transformation of Susceptible Cultured Cells

  2010cited by this paper
• Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer.

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies.

  2008cited by this paper
• Circulating mutant DNA to assess tumor dynamics

  2008cited by this paper
• Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia

  2008cited by this paper
• Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats.

  2006cited by this paper
• Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.

  2005cited by this paper
• Effects of preanalytical factors on the molecular size of cell-free DNA in blood.

  2005cited by this paper
• Detection and quantification of mutations in the plasma of patients with colorectal tumors.

  2005cited by this paper
• Molecular Detection of APC, K-ras, and p53 Mutations in the Serum of Colorectal Cancer Patients as Circulating Biomarkers

  2004cited by this paper
• Effects of blood-processing protocols on cell-free DNA quantification in plasma.

  2003cited by this paper
• Quantification of free circulating DNA as a diagnostic marker in lung cancer.

  2003cited by this paper
• O-297 Quantification of free circulating DNA as a diagnostic marker in lung cancer

  2003cited by this paper
• Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma.

  2003cited by this paper
• Changes in concentration of DNA in serum and plasma during storage of blood samples.

  2003cited by this paper
• Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis

  2002cited by this paper
• Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients.

  2001cited by this paper
• DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

  2001cited by this paper
• Alu Repeat Sequences Are Present in Increased Proportions Compared to a Unique Gene in Plasma/Serum DNA

  2001cited by this paper
• Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma.

  2000cited by this paper
• Microsatellite alterations plasma DNA of primary breast cancer patients.

  2000cited by this paper
• Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer.

  1999cited by this paper
• Digital PCR.

  1999cited by this paper
• Rapid clearance of fetal DNA from maternal plasma.

  1999cited by this paper
• Point mutations of the N‐ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia

  1994cited by this paper
• Neoplastic characteristics of the DNA found in the plasma of cancer patients.

  1989cited by this paper
• Free DNA in the serum of cancer patients and the effect of therapy.

  1977cited by this paper
• Les acides nucleiques du plasma sanguin chez l' homme

  1948cited by this paper

• Extrachromosomal circular DNA: a potential clinical therapeutic target in malignant tumors.

  2026cites this paper
• Exploring correlations of CA19-9 with serum enzyme ratios: can layered biomarker strategies enhance prognostic accuracy in pancreatic cancer?

  2026cites this paper
• Circulating extracellular vesicle DNA (EV-DNA) and cell-free DNA in ovarian cancer: pathological relevance and diagnostic applications

  2026cites this paper
• Pre-analytical optimization of cell-free DNA and extracellular vesicle-derived DNA for mutation detection in liquid biopsies.

  2026cites this paper
• Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy.

  2026cites this paper
• Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: Clinical Utility, Trials, and Future Directions

  2025cites this paper
• Detection of KRAS, NRAS and BRAF Mutations in Liquid Biopsy from Patients with Colorectal Cancer

  2025cites this paper
• The Application of Microfluidic Chips in Primary Urological Cancer: Recent Advances and Future Perspectives

  2025cites this paper
• Adapting Clinical Chemistry Plasma as a Source for Liquid Biopsies

  2025cites this paper
• Novel proteomics biomarkers of recurrent pregnancy loss reflect the dysregulation of immune interactions at the maternal-fetal interface

  2025cites this paper
• Treatment-Agnostic Joint Modeling of Longitudinal Circulating Tumor DNA Predicts Survival across First-Line Regimens in Metastatic Non-Squamous NSCLC.

  2025cites this paper
• Tumor Budding Grade and T Stage as Recurrence Predictors of High-risk Stage II Colorectal Cancer

  2025cites this paper
• Liquid Biopsy and Epigenetic Signatures in AML, ALL, and CNS Tumors: Diagnostic and Monitoring Perspectives

  2025cites this paper
• Development of a technique for diagnosis and screening of superficial bladder cancer by cell-pellet DNA from urine sample.

  2025cites this paper
• Integrating artificial intelligence with circulating tumor DNA for non-small cell lung cancer: opportunities, challenges, and future directions

  2025cites this paper
• CRISPR/Cas12a-calibrated biosensor for accurate detection of low-frequency single nucleotide variants via loop-assisted adjustable entropy-driven catalytic reaction

  2025cites this paper
• Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer.

  2025cites this paper
• Emerging biomarkers for early detection of lung cancer

  2025cites this paper
• Circulating tumor DNA in patients with cancer: insights from clinical laboratory

  2025influential citation
• ADN tumoral circulante en pacientes con cáncer: perspectivas desde el laboratorio clínico

  2025influential citation
• Extraction and purification of short DNA fragments from plasma using aqueous two-phase systems for liquid biopsy

  2025cites this paper
• Label-Free Optical Biosensor for Analysis of Binding Kinetics of Smart Nanomaterials with Ligands

  2025cites this paper
• Integrating Circulating Tumor DNA into Clinical Management of Colorectal Cancer: Practical Implications and Therapeutic Challenges

  2025cites this paper
• Circulating tumor DNA: a biomarker for oncology drug development in phase I clinical trials?

  2025cites this paper
• Liquid Biopsy in CRC Management: Early Detection, Minimal Residual Disease, and Therapy Optimization—Clinical Evidence and Challenges

  2025cites this paper
• Application of cfDNA methylation in cancer prognostic assessment: Progress and challenges (Review).

  2025cites this paper
• CRISPR with a Double Mismatch Guide RNA Enhances Detection Sensitivity for Low-Frequency Single-Base EGFR Mutation in Circulating Cell-Free DNA of Lung Cancer Patients

  2025cites this paper
• cfOncoXpress: Tumor gene expression prediction from cell-free DNA whole-genome sequences

  2025cites this paper
• Liquid biopsy and circulating tumor cell analysis.

  2025cites this paper
• Clinical Implications of Circulating Tumor DNA in Multiple Myeloma and Its Precursor Diseases

  2025cites this paper
• Single-tube, Switched Temperature Amplicon Barcoding (STAB-seq) for Multiplex Detection of Rare Mutations in Circulating Tumor DNA.

  2025cites this paper
• Comparative analysis of whole-genome sequencing of tumor and cfDNA in a neuroblastoma patient: a case report

  2025cites this paper
• Detection of circulating tumor DNA (ctDNA) using a magnetic bead-assisted fluorescent and electrochemical biosensor system

  2025cites this paper
• Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies

  2025cites this paper
• Evaluation of Raw Cell-Free DNA Sequences for Gastric Cancer Detection.

  2025cites this paper
• Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA

  2025cites this paper
• Evaluation of ctDNA-based ESR1 testing in breast cancer: results from the first external quality assessment scheme in China

  2025influential citation
• Advance and challenge of DNA methylation as cancer biomarkers for risk stratification, screening and early detection

  2025cites this paper
• Language model enables end-to-end accurate detection of cancer from cell-free DNA

  2024cites this paper
• Microfluidic bead-based biosensor: Ultrasensitive ctDNA detection based on duplex-functional split-DNAzyme and dendritic enzyme-free signal amplification.

  2024cites this paper
• Cell‐free DNA‐associated multi‐feature applications in cancer diagnosis and treatment

  2024cites this paper
• Optical nanomaterial-based detection of biomarkers in liquid biopsy

  2024cites this paper
• Critical Factors in the Analytical Work Flow of Circulating Tumor DNA-Based Molecular Profiling.

  2024cites this paper
• The Circulating Biomarkers League: Combining miRNAs with Cell-Free DNAs and Proteins

  2024cites this paper
• Immune biomarkers and predictive signatures in gastric cancer: Optimizing immunotherapy responses.

  2024cites this paper
• Liquid biopsy for CNS lymphoma: CSF exosomes and CSF exosomal miR-15a, miR-21, miR-155, miR-210, and miR-19b are promising biomarkers for diagnosis

  2024cites this paper
• Circulating Tumor Cells in Cancer Diagnosis, Therapy, and Theranostics Applications: An Overview of Emerging Materials and Technologies.

  2024cites this paper
• Liquid Biopsy : A Narrative Review

  2024cites this paper
• TOTEM: a multi-cancer detection and localization approach using circulating tumor DNA methylation markers

  2024cites this paper
• Circulating Tumor Cells: Origin, Role, Current Applications, and Future Perspectives for Personalized Medicine

  2024cites this paper
• Circulating free DNA as a diagnostic marker for echinococcosis: a systematic review and meta-analysis

  2024cites this paper
• Liquid biopsy for diagnostic and prognostic evaluation of melanoma

  2024cites this paper
• Advancements in Understanding the Hide-and-Seek Strategy of Hibernating Breast Cancer Cells and Their Implications in Oncology from a Broader Perspective: A Comprehensive Overview

  2024cites this paper
• Levels of circulating tumor DNA correlate with tumor volume in gastro‐intestinal stromal tumors: an exploratory long‐term follow‐up study

  2024cites this paper
• Recent Advances in Plasmonics for Liquid Biopsy: A Short Review

  2024cites this paper
• Current Issues of Next-Generation Sequencing-Based Circulating Tumor DNA Analysis in Colorectal Cancer

  2024cites this paper
• ctDNA in the reading room: A guide for radiologists.

  2024cites this paper
• The Role of Circulating Tumor Cells as a Liquid Biopsy for Cancer: Advances, Biology, Technical Challenges, and Clinical Relevance

  2024influential citation
• Circulating Tumor Cells in Oral Cancer

  2024cites this paper
• Clinical applications and perspectives of circulating tumor DNA in gastric cancer

  2024cites this paper
• CRISPR/Cas detection with nanodevices: moving deeper into liquid biopsy.

  2024cites this paper
• Decreased Expression of Placental Proteins in Recurrent Pregnancy Loss: Functional Relevance and Diagnostic Value

  2024cites this paper
• A Quest for Survival: A Review of the Early Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present

  2024cites this paper
• Mitochondrial DNA as a target for analyzing the biodistribution of cell therapy products

  2024cites this paper
• Screening and identification of serum exosomal protein ZNF587B in liquid biopsy for ovarian cancer diagnosis.

  2024cites this paper
• Strategic approaches in oral squamous cell carcinoma diagnostics using liquid biopsy

  2024cites this paper
• On-Chip Magnetic Extraction of Circulating Cell-Free DNA from Biological Samples.

  2024cites this paper
• Immunomultiple PCR-based electrochemical and lateral flow strategy for the simultaneous detection of liver cancer tumor markers

  2023cites this paper
• A scenario‐drafting study to explore potential future implementation pathways of circulating tumor DNA testing in oncology

  2023cites this paper
• Circulating Tumor DNA and Management of Colorectal Cancer

  2023cites this paper
• The utility of liquid biopsy in clinical genetic diagnosis of cancer and monogenic mosaic disorders

  2023cites this paper
• Liquid biopsy: creating opportunities in brain space

  2023cites this paper
• Tweezer PCR: A Highly Specific Method for Accurate Identification of Low-Abundance Mutations.

  2023cites this paper
• Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis

  2023cites this paper
• Saliva as a potential non-invasive liquid biopsy for early and easy diagnosis/prognosis of head and neck cancer

  2023cites this paper
• Minimal residual disease monitoring via ctDNA: a case report of Lynch syndrome with synchronous colorectal cancer and review of literature

  2023cites this paper
• CÂNCER: UMA REVISÃO INTEGRATIVA POR ESTUDANTES DE MEDICINA

  2023influential citation
• Electrochemiluminescent CdS Quantum Dots Biosensor for Cancer Mutation Detection at Different Positions on Linear DNA Analytes.

  2023cites this paper
• Concordance analysis of cerebrospinal fluid with the tumor tissue for integrated diagnosis in gliomas based on next-generation sequencing

  2023cites this paper
• Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis

  2023cites this paper
• Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients

  2023cites this paper
• Bile liquid biopsy in biliary tract cancer.

  2023cites this paper
• DELFMUT: duplex sequencing-oriented depth estimation model for stable detection of low-frequency mutations

  2023cites this paper
• Interlaboratory evaluation of quality control methods for circulating cell-free DNA extraction.

  2023cites this paper
• Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma

  2023cites this paper
• Evaluating Stacked Methylation Markers for Blood-Based Multicancer Detection

  2023cites this paper
• Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma

  2023cites this paper
• Mismatch-Guided Deoxyribonucleic Acid Assembly Enables Ultrasensitive and Multiplex Detection of Low-Allele-Fraction Variants in Clinical Samples.

  2023cites this paper
• Circulating Tumor DNA Dynamics: A New Approach in Revolutionizing Cancer Management

  2023cites this paper
• Liquid Biopsies: Emerging role and clinical applications in solid tumours

  2023cites this paper
• Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects.

  2023cites this paper
• Multi-cancer early detection liquid biopsy testing: A predictive genetic test not quite ready for prime time

  2023cites this paper
• Systematic and Comprehensive Analysis of tRNA-Derived Small RNAs Reveals Their Potential Regulatory Roles and Clinical Relevance in Sarcoidosis

  2023cites this paper
• Identification of Immunoglobulin Gene Rearrangement Biomarkers in Multiple Myeloma through cfDNA-Based Liquid Biopsy Using tchDNA-Seq

  2023cites this paper
• Advances in liquid biopsy-based markers in NSCLC.

  2023cites this paper
• Role of Circulating Tumor DNA in Colorectal Cancer.

  2023cites this paper
• Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer

  2023cites this paper
• Target-independent hybridization chain reaction-fluorescence resonance energy transfer for sensitive assay of ctDNA based on Cas12a.

  2023cites this paper
• Induced crystal formation in urine as an easily accessible indicator of tumor stage? – A translational explorative study

  2023cites this paper
• Pancreatic Cancer Biomarkers: Oncogenic Mutations, Tissue and Liquid Biopsies, and Radiomics—A Review

  2023cites this paper